Successful Transition From Insulin to Sulfonylurea Therapy in a Patient With Monogenic Neonatal Diabetes Owing to a KCNJ11 P333L Mutation

Ítems similars

• Successful Transition From Insulin to Sulfonylurea Therapy in a Patient With Monogenic Neonatal Diabetes Owing to a KCNJ11 P333L Mutation. Diabetes Care 2013;36:e201
  per: Philla, Katherine Q., et al.
  Publicat: (2014)
• Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations
  per: Letourneau, Lisa R., et al.
  Publicat: (2019)
• Precision medicine in KCNJ11 permanent neonatal diabetes
  per: Greeley, Siri Atma W, et al.
  Publicat: (2018)
• Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes
  per: Thurber, Brian W., et al.
  Publicat: (2015)
• Visuomotor Performance in KCNJ11-Related Neonatal Diabetes Is Impaired in Children With DEND-Associated Mutations and May Be Improved by Early Treatment With Sulfonylureas
  per: Shah, Reshma P., et al.
  Publicat: (2012)